Home > Browse Issues > Vol.38 No.12
The Progress of Oncolytic Vaccinia Viruses Modified Genetically for the Tumor Treatment
Li Danyang1,2, Tang Hui2*
1College of Medicine, Kunming University of Science and Technology, Kunming 650504, China;
2Institute of Basic Medical Sciences, Affiliated Hospital of Kunming University of Science and Technology,The First People’s Hospital of Yunnan Province, Kunming 650032, China
2Institute of Basic Medical Sciences, Affiliated Hospital of Kunming University of Science and Technology,The First People’s Hospital of Yunnan Province, Kunming 650032, China
Abstract: Current tumor treatments include surgery， radiotherapy， chemotherapy， thermotherapy， and biological/immunological therapy. The use of oncolytic viruses for the tumor treatment is an emerging field of tumor therapy. Oncolytic virotherapy， which exploits replication-competent viruses to selectively infect and destroy tumorous cells while sparing normal cells and tissues， is an emerging therapy for the biological/immunological therapy of tumor. Gene therapy has always been an important strategy for the biological treatment of tumor.Making use of genetic engineering strategy to insert anti-tumor genes in oncolytic viral vector， and combining gene therapy with virotherapy become a gene-viro-therapy involved strong killing effect. Vaccinia virus has emerged as an attractive oncolytic virus vector especially when used as genetic therapy of tumor. It is a important strategy to modify vaccinia viruses through genetic engineering strategy which enhance their anti-tumor efficacy. At present， oncolytic vaccinia virus genetically modifies mainly based on the backbone of Wyeth strain， Western Reverse (WR) strain， Lister strain， Copenhagen strain and Tian Tan strain. This review addresses some of the common forms of genetically modified vaccinia viruses and describes the progress of genetically modified vaccinia virus vector based tumor therapy.
CN
EN